Ozanimod: A Review in Ulcerative Colitis
Author:
Open Access
- 22 August 2022
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 82 (12) , 1303-1313
Abstract
Ozanimod (Zeposia®) is the first sphingosine-1-phosphate receptor (S1PR) modulator to be approved for the treatment of adults with moderately to severely active ulcerative colitis in the USA, and in adults with moderately to severely active ulcerative colitis who have had an inadequate or lost response to, or were intolerant of, either conventional therapy or a biologic in the EU. An oral agent, ozanimod is administered once daily as induction and maintenance therapy. In the randomized, double-blind, multinational phase 2 Touchstone and phase 3 True North clinical trials, ozanimod was effective in inducing clinical remission and maintaining remission relative to placebo in adults with moderately to severely active ulcerative colitis. Ozanimod was generally well tolerated in these studies, with manageable or transient adverse events (AEs). Current data from the Touchstone and True North open-label extensions are consistent with the primary studies with respect to therapeutic efficacy and tolerability, with no new safety signals observed. Although further data will be beneficial, ozanimod expands the treatment options for adults with moderately to severely active ulcerative colitis.Keywords
This publication has 45 references indexed in Scilit:
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adultsGut, 2019
- Innovations in Oral Therapies for Inflammatory Bowel DiseaseDrugs, 2019
- Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR AgonistsFrontiers in Pharmacology, 2019
- ACG Clinical Guideline: Ulcerative Colitis in AdultsAmerican Journal of Gastroenterology, 2019
- Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor ModulatorClinical Pharmacology in Drug Development, 2017
- Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biologyWorld Journal of Gastroenterology, 2017
- Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc StudyClinical Pharmacology in Drug Development, 2017
- Ulcerative colitisThe Lancet, 2017
- Ozanimod Induction and Maintenance Treatment for Ulcerative ColitisNew England Journal of Medicine, 2016
- Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P1) and receptor‐5 (S1P5) agonist with autoimmune disease‐modifying activityBritish Journal of Pharmacology, 2016